1. Home
  2. FHTX

FHTX

Foghorn Therapeutics Inc.

Logo Foghorn Therapeutics Inc.

Health Care

Medicinal Chemicals and Botanical Products

Nasdaq

as 04-23-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Founded: 2015 Country:
N/A
Employees: N/A City: CAMBRIDGE
Market Cap: 225.6M IPO Year: 2020
Target Price: $15.40 AVG Volume (30 days): 162.6K
Analyst Decision: N/A Number of Analysts: N/A
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.34 EPS Growth: N/A
52 Week Low/High: $2.70 - $9.97 Next Earning Date: 01-01-0001
Revenue: $34,155,000 Revenue Growth: 77.63%
Revenue Growth (this year): -12.73% Revenue Growth (next year): 16.89%

Share on Social Networks: